Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. (Q38733785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

title

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Patrick J Engelberts

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Janine Schuurman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Tom van Meerten

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Tom Vink

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Esther C W Breij

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Stefanie Derer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Thomas Valerius

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Frank J Beurskens

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Marleen Voorhorst

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Joost M Bakker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Wendy J M Mackus

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

Jan G J van de Winkel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

2 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

published in

Journal of Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

volume

197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

4829-4837

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

26 March 2020

cites work

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Differential activation of human and guinea pig complement by pentameric and hexameric IgM.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Complement is activated by IgG hexamers assembled at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Oligomeric antigen receptors: a new view on signaling for the selection of lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

B cell antigen receptors of the IgM and IgD classes are clustered in different protein islands that are altered during B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.1600811

21 January 2018

Identifiers

DOI

10.4049/JIMMUNOL.1600811

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27807190 AND SRC:MED&resulttype=core&format=json

26 March 2020

1 reference